

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12Q 1/68, C12P 19/34, C07H 21/02, 21/04, 21/00, B01D 15/08, C02F 1/28		A1	(11) International Publication Number: WO 99/23257
			(43) International Publication Date: 14 May 1999 (14.05.99)
(21) International Application Number: PCT/US98/23265		(74) Agent: WALKER, William, B.; Transgenomic, Inc., 2032 Concourse Drive, San Jose, CA 95131 (US).	
(22) International Filing Date: 30 October 1998 (30.10.98)			
(30) Priority Data: 60/064,437 31 October 1997 (31.10.97) US 09/039,061 13 March 1998 (13.03.98) US 09/058,337 10 April 1998 (10.04.98) US 09/058,580 10 April 1998 (10.04.98) US 09/129,105 4 August 1998 (04.08.98) US 60/103,313 6 October 1998 (06.10.98) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MU, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, S TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIP patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): TRANSGE- NOMIC, INC. [US/US]; Suite D-200, 1620 Oakland Road, San Jose, CA 95131 (US).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): SKLAR, Jeffrey, L. [US/US]; 49 Princeton Road, Chestnut Hill, MA 02167 (US). GJERDE, Douglas, T. [US/US]; 12995 Woodside Drive, Saratoga, CA 95070 (US). LAMB, Kimberly, A. [US/US]; 5102 Capitol Avenue #17, Omaha, NE 68132 (US). HANNA, Christopher, P. [US/US]; 181 Central Street #1B, Somerville, MA 02144 (US).			
(54) Title: METHOD OF DETECTING MUTANT DNA BY MIPC AND PCR			
(57) Abstract <p>A method for detecting a putative mutant DNA in a sample of DNA includes the steps of amplifying the sample of DNA using PCR, hybridizing the amplified sample to form a mixture of homoduplexes and heteroduplexes; separating the mixture into fractions by Denaturing Gradient Ion Polynucleotide Chromatography; and blind collecting the eluted fractions at a retention time corresponding to the retention time of the heteroduplex. The DNA in the blind collected fractions can be PCR amplified to obtain an increased amount of heteroduplex relative to homoduplex. The method is useful for determining the remission status of a patient in which the tissue-derived DNA sample contains a large background of wild type or where the putative mutant DNA is below the limit of detection.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION**METHOD OF DETECTING MUTANT DNA BY MIPC AND PCR****FIELD OF THE INVENTION**

The present invention concerns a chromatographic method for detection of
5 mutations in nucleic acids.

BACKGROUND OF THE INVENTION

The early diagnosis of certain diseases, especially cancer, can save many
lives. In the case of cancer, and other diseases of genetic origin, early detection
often depends on the availability of an appropriate analytical method which can
10 accurately and reliably detect a putative mutation in DNA samples. This problem
is exacerbated by the fact that such samples generally contain a very small
population of cells containing mutant DNA in the presence of a very large
predominantly normal cell population containing wild type DNA. Any separation
technique which is capable of detecting mutant DNA in the presence of wild type
15 would fail under these circumstances because the concentration of mutant DNA
is simply too low to be detected relative to wild type. That is to say, the
concentration of mutant DNA may be too low to detect in absolute terms.

Alternatively, the concentration of mutant DNA may be sufficient to detect, but will
be completely obscured because of the very large relative amount of wild type in
20 the sample.

Increasing the amount of mutant DNA by PCR amplification of the sample
would not solve the problem described above. The mutant and wild type DNA in
the sample are very similar. In fact, their sequence may differ by only a single
base pair. Therefore, the primers which would be used to amplify the mutant

DNA would also amplify the wild type since both are present in the sample. As a result, the relative amounts of mutant and wild type DNA would not change.

Following radiation or chemotherapy, cancer patients are monitored for the presence of residual cancer cells to determine whether the patients are in
5 remission. The effectiveness of these treatments can be monitored if small levels of residual cancer cells could be detected in a predominantly large wild type population. Traditionally, the remission status is assessed by a pathologist who conducts histological examination of tissues samples. However, these visual methods are largely qualitative, time-consuming, and costly. At best, the
10 sensitivity of these methods permits detection of about 1 cancerous cell in 100 cells.

Analysis of DNA samples has historically been done using gel electrophoresis. Capillary electrophoresis has also been used to separate and analyze mixtures of DNA. However, these methods cannot distinguish point
15 mutations from homoduplexes having the same base pair length.

Gel based analytical methods, such as denaturing gradient gel electrophoresis and denaturing gradient gel capillary electrophoresis, can detect mutations in heteroduplex DNA strands under "partially denaturing" conditions. The term "partially denaturing" means the separation of a mismatched base pair
20 (caused by temperature, pH, solvent, or other known factors) in a DNA double strand while the remainder of the double strand remains intact. However, these gel based techniques are operationally difficult to implement and require highly skilled personnel. In addition, the analyses are lengthy and require a great deal of set-up time. A denaturing capillary gel electrophoresis analysis of a 90 base

pair fragment takes more than 30 minutes and a denaturing gel electrophoresis analysis may take 5 hours or more. The long analysis time of the gel methodology is further exacerbated by the fact that the movement of DNA fragments in a gel is inversely proportional, in a geometric relationship, to their length. Therefore, the analysis time of longer DNA fragments can be often be untenable. Sample recovery of DNA fragments separated on a gel is difficult and time consuming, requiring specialized techniques.

In addition to the deficiencies of denaturing gel methods mentioned above, these techniques are not always reproducible or accurate since the preparation of a gel slab and running an analysis can be highly variable from one operator to another. As a result, the mobility of a DNA fragment is often different on different gel slabs and even in one lane, compared to another on the same gel slab. The problems and deficiencies of gel based DNA separation methods are well known in the art and are described in "Laboratory Methods for the Detection of Mutations and Polymorphisms", ed. G. R. Taylor, CRC Press (1997).

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a sensitive and reproducible method which would enable the detection of small amounts of mutant DNA in the presence of a relatively large amount of wild type DNA, wherein such mutations would otherwise go undetected. It is a further object of the invention to provide an analytical method which is reproducible, reliable, inexpensive, can be automated and can be used for high throughput sample screening.

In one aspect, the present invention is a method for detecting a putative mutant DNA in a sample of DNA, the method including the steps of (a) amplifying the sample of DNA using PCR, (b) hybridizing the amplified sample to form a mixture of homoduplexes and heteroduplexes, (c) separating the product of step 5 (b) into fractions by Denaturing Matched Ion Polynucleotide Chromatography, and (d) blind collecting the fractions from step (c) at a retention time corresponding to the retention time of the heteroduplex. The method preferably includes amplifying the fractions collected in step (d) using PCR to obtain an increased amount of heteroduplex relative to homoduplex. The method can also 10 include repeating steps (a) through (d); in a preferred method these steps are repeated until the relative amount of mutant to wild type DNA is increased by an enhancement factor of at least 10 to 1000. The DNA sample can contain a large background of wild type. The putative mutant DNA can be below the limit of detection. The identity of the heteroduplex can be confirmed using standard 15 methods. In a preferred embodiment, the DNA sequence of the wild type DNA and the mutant DNA are known. In a typical analysis using the method of the invention, the mutant DNA differs from wild type DNA by at least one base pair. In a preferred embodiment, the same PCR primers are used to amplify both the mutant DNA and the wild type DNA in the sample. In another preferred 20 embodiment, the retention time used in the blind collection of the heteroduplex in step (d) was previously determined from a reference standard. A preferred reference standard is obtained by separating a standard mixture of homoduplex and heteroduplex, having the same base pair sequence as the sample, by Matched Ion Polynucleotide Chromatography.

In a preferred embodiment of the invention, the separation of the product by Denaturing Matched Ion Polynucleotide Chromatography is effected with an MIPC column containing a stationary phase separation media, and the column is treated before the separating step with a solution for removing any residual DNA
5 from prior separations. For example, the column can be treated before the separating step with from 50 μ L to 1 ml of tetrasodium EDTA adjusted to a pH of 13 with sodium hydroxide. Other treatments for washing a column can also be used alone or in combination with those indicated hereinabove. These treatments include exposing the separation medium to high concentrations of
10 organic solvent (e.g., up to 100% acetonitrile) or exposing the medium to denaturants such as urea or formamide. The column can also be treated by reverse flushing the a washing solution.

In another aspect, the present invention is a method for screening a tissue sample for cancerous cells by detecting a putative mutant DNA in the DNA of the
15 sample, the method including the steps of (a) amplifying the sample DNA using PCR, (b) hybridizing the amplified sample to form a mixture of homoduplexes and heteroduplexes, (c) separating the product of step (b) into fractions by Denaturing Matched Ion Polynucleotide Chromatography, and (d) blind collecting the fractions from step (c) at a retention time corresponding to the retention time of
20 the heteroduplex.

The method preferably includes amplifying the fractions collected in step (d) using PCR to obtain an increased amount of heteroduplex relative to homoduplex. The method can also include repeating steps (a) through (d); in a preferred method these steps are repeated until the relative amount of mutant to

wild type DNA is increased by an enhancement factor of at least 10 to 1000. The DNA sample can contain a large background of wild type. The putative mutant DNA can be below the limit of detection. The identity of the heteroduplex can be confirmed using standard methods. In a preferred embodiment, the DNA sequence of the wild type DNA and the mutant DNA are known. In a typical analysis using the method of the invention, the mutant DNA differs from wild type DNA by at least one base pair. In a preferred embodiment, the same PCR primers are used to amplify both the mutant DNA and the wild type DNA in the sample. In another preferred embodiment, the retention time used in the blind collection of the heteroduplex in step (d) was previously determined from a reference standard. A preferred reference standard is obtained by separating a standard mixture of homoduplex and heteroduplex, having the same base pair sequence as the sample, by Matched Ion Polynucleotide Chromatography.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of hybridization of wild type DNA strand with homozygous mutant strand showing the production of two homoduplexes and two heteroduplexes.

FIG. 2 is a DMIPC chromatogram showing the separation of a standard mixture of FIG. 1.

FIG. 3 are DMIPC chromatograms demonstrating mutation detection using blind collection.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates, therefore, to the unambiguous detection and identification of very small amounts of heteroduplex fragments containing mutant

DNA in the presence of a relatively very large amount of known wild type using a recently developed chromatographic method called Denaturing Matched Ion Polynucleotide Chromatography (DMIPC), a method analogous to Matched Ion Polynucleotide Chromatography (MIPC).

5 MIPC separates DNA fragments based on their base pair length (U.S. Patent No. 5,585,236 to Bonn (1996); Huber, et al., Chromatographia 37:653 (1993); Huber, et al., Anal. Biochem. 212:351 (1993)). These references and the references contained therein are incorporated herein in their entireties. When MIPC analyses are performed at partially denaturing temperature, the process is
10 called DMIPC. These separation methods obviate the deficiencies of gel based methods and make possible the collection and identification of mutant DNA fragments whose concentration relative to wild type is small, and may be below the detection limits of a detector. Alternatively, MIPC and DMIPC make possible the collection and identification of mutant fragments which would be obscured by
15 a relatively large amount of wild type in a sample. This method will be discussed in detail herein below.

The term "Matched Ion Polynucleotide Chromatography" as used herein is defined as a process for separating single and double stranded polynucleotides using non-polar separation media, wherein the process uses a counter-ion agent,
20 and an organic solvent to release the polynucleotides from the separation media. MIPC separations are complete in less than 10 minutes, and frequently in less than 5 minutes. MIPC systems (WAVE™ DNA Fragment Analysis System, Transgenomic, Inc. San Jose, CA) are equipped with computer controlled ovens which enclose the columns and sample introduction areas.

MIPC uses unique non-polar separation media which comprises organic polymers, silica media having a non-polar surface comprising coated or covalently bound organic polymers or covalently bound alkyl and/or aryl groups, and continuous non-polar separation media, i.e., monolith or rod columns such as non-polar silica gel or organic polymer. The separation media used in MIPC can be porous or non-porous. A detailed description of the MIPC separation process, MIPC separation media, and MIPC systems is found in U.S. Patent No. 5,772,889 (1998) to Gjerde and in co-pending U.S. Patent Applications Nos. 09/058,580 filed March 10, 1998; 09/058,337 filed March 10, 1998; 09/081,040 filed May 18, 1998; 09/080,547 filed May 18, 1998; and in the U.S. Patent Application identified by attorney docket no. TRAN1-122 filed October 9, 1998 and entitled "Modifying Double stranded DNA to Enhance Separations by Matched Ion Polynucleotide Chromatography". MIPC systems and separation media are commercially available (Transgenomic, Inc. San Jose, CA). The entire MIPC analysis can be automated by means of a desk top computer and a sample auto-injector. Analytical data for each sample can be analyzed in real time, or collected and stored in a computer memory device for analysis at a later time.

The use of MIPC at partially denaturing temperature, i.e., DMIPC, to detect mutations has been described in a co-pending U.S. Patent Application No. 09/129,105 filed August 4, 1998. This application and the references contained therein are incorporated herein in their entireties.

An important requirement for effective blind collections according to this invention is the absence from the separation media of any DNA fragments or other contaminants from prior separations. One procedure for insuring this

prerequisite is cleaning the column after each separation with a suitable cleaning solution, for example, from 50 μ L to 1 ml of tetrasodium EDTA adjusted to a pH of 13 with sodium hydroxide. Applicants have found that other treatments for washing a column can also be used alone or in combination with those indicated
5 hereinabove. These treatments include exposing the separation medium to high concentrations of organic solvent (e.g., up to 100% acetonitrile) or exposing the medium to denaturants such as urea (e.g., 5M) or formamide. The column can also be treated by reverse flushing with a washing solution.

The present invention provides a method for detecting mutations in a
10 sample containing a relatively large amount of wild type, wherein the concentration of the mutation is below the limits of detection a detector. Alternatively, the invention provides a method for detecting mutations when the concentration of mutant DNA in a sample may be sufficient to detect, but the mutant DNA is not seen because it is obscured by the relatively large amount of
15 wild type in the sample. The invention takes advantage of the unique and surprising attributes of MIPC and DMIPC to accomplish the objective of detecting mutations in such samples, wherein the wild type and mutant are known.

Preferably, the PCR primers are selected to yield fragments for which complete resolution of heteroduplexes from homoduplexes can be achieved by
20 MIPC. Details for suitable primer selection are provided in copending U.S. Patent Application Serial No. 09/129,105 filed August 4, 1998, the entire contents of which are hereby incorporated by reference.

MIPC separates DNA fragments on the basis of their base pair length. The method is highly reproducible. Therefore, columns do not have to be

calibrated from sample to sample or from day to day. A DNA fragment of a particular base pair length will elute from an MIPC column at a specific retention time which is reliably reproducible. This characteristic, coupled with the automation, sample collection, and rapid sample analysis capabilities of MIPC

5 make this method uniquely suited for detection of minute quantities of mutations in the presence of a large background of wild type.

Applicants have taken advantage of the reproducible retention time of a particular fragment in MIPC separations to purify and isolate mutant fragments by "blind collection". The term "blind collection" is defined herein to mean the

10 collection of mobile phase flowing through an MIPC column over a specific time interval subsequent to application of a DNA sample to the column. More specifically, "blind collection" refers to collecting mobile phase during the retention time interval corresponding to a previously determined retention time interval of a DNA fragment standard. Since the relationship between MIPC

15 retention time and base pair length is highly reproducible, it is not necessary to detect a desired fragment with a detector in order to know when to collect the fragment. Column mobile phase is simply collected at the predetermined and expected retention time of a desired fragment.

In a preferred embodiment, the invention comprises a number of steps

20 which eliminate any ambiguity regarding the presence or absence of a particular mutant fragment in a sample when the sample contains a large amount of wild type DNA relative to a putative mutation. These steps are described hereinbelow.

Since the base sequence of the sample wild type DNA and the putative mutation are known, standards of these materials are combined and hybridized. Hybridization is effected by heating the combined standards to about 90°C, then slowly cooling the reaction to ambient temperature over about 45 to 60 minutes.

- 5 During hybridization, the duplex strands in the sample denature, i.e., separate to form single strands. Upon cooling, the strands recombine. If a mutant strand was present in the sample having at least one base pair difference in sequence than wild type, the single strands will recombine to form a mixture of homoduplexes and heteroduplexes. In this manner, a standard mixture of
- 10 homoduplexes and heteroduplexes is formed as depicted schematically in FIG. 1. The standard mixture contains the same homoduplexes and heteroduplexes present in a sample which contains a putative mutation, albeit not in the same ratio. This standard mixture cannot be separated by MIPC under normal conditions, since the heteroduplex and homoduplex have the same base pair
- 15 length. However, when MIPC is performed at a temperature sufficiently elevated to selectively and partially denature a heteroduplex at the site of base pair mismatch (DMIPC), the partially denatured heteroduplex will separate from a homoduplex having the same base pair length. Therefore, the hybridized standard mixture is applied to a MIPC column and a separation is performed
- 20 under DMIPC conditions. The chromatogram so produced shows a separation of the homoduplexes and heteroduplexes as shown in FIG. 2. The retention times of the separated homoduplex and heteroduplex standards can then be used to predict the retention times of putative mutations having a concentration too low to be detected by a detector. Alternatively, the retention times of the separated
- 25 homoduplex and heteroduplex standards can then be used to predict the

retention times of putative mutations in samples wherein the mutation signal is obscured by the wild type signal.

Having determined the retention times of the standards, a sample containing a putative mutation is amplified using PCR to increase the total
5 quantity of sample. Since the sequence is known, primers can be designed to maximize the fidelity of replication and minimize the formation of reaction artifacts and by-products. Approaches to primer design and PCR optimization for mutation detection by DMIPC are discussed in co-pending U.S. Patent Application 09/129,105 filed August 4, 1998. However, wild type and mutant DNA
10 strands in a sample have a nearly identical base sequence. A mutation may contain only one base pair difference compared to wild type. Therefore, primers cannot be designed to selectively anneal to, and preferentially amplify the mutant strand in the presence of wild type. Therefore, when such a sample is amplified using PCR, the ratio of mutant to wild type in the amplified product will be the
15 same as in the original sample.

When the amplified sample is analyzed using MIPC a single major peak will be seen in the resulting chromatogram. This peak represents the combined wild type and mutant DNA, if the latter is present. No separation is achieved because the mutant and wild type DNA have the same base pair length.
20 Therefore, the amplified sample is hybridized and analyzed under partially denaturing conditions by DMIPC. However, the heteroduplex corresponding to the putative mutation, if present, will not be seen by the detector either because its concentration is below the detection limits of the detector or because the ratio of wild type to putative mutation is very large so that the wild type homoduplex
25 peak obscures the heteroduplex peak.

In either case, the heteroduplex corresponding to the mutant DNA in the original sample need not be seen as a chromatographic peak to be determined. Having previously identified the retention time of the heteroduplex standard, the mobile phase is "blind collected" from the column at the expected retention time.

5 In the operation of the invention, a tissue sample of at least about 100,000 cells is obtained for analysis. It is possible that, despite the initial DNA amplification, there will still be too little heteroduplex to detect. It is also possible that despite the separation of the homoduplex and heteroduplex, some homoduplex may have been collected along with the heteroduplex at the
10 expected heteroduplex retention time, contaminating the heteroduplex and making it difficult to determine without ambiguity whether or not a mutation was present in the original sample. However, the ratio of homoduplex to heteroduplex will now be increased in favor of the heteroduplex compared to the ratio in the original sample.

15 The "blind collected" mobile phase described hereinabove preferably is concentrated, e.g., by evaporation of the mobile phase. If a mutation was present in the original sample, the residue will now be enriched in the heteroduplex. This heteroduplex enriched residue is amplified again by PCR and the products are hybridized. The hybridized products of the second PCR amplification will now
20 contain an increased amount of heteroduplex relative to homoduplex. This process is described in Example 1 and depicted in FIG. 3. The evaporation can be effected with standard and conventional DNA solution evaporation equipment, for example, the SPEEDVAC evaporator (Model UCS 100 Universal Speed Vac system, Savant Instruments, Inc, Hayward, CA)

The steps comprising the method of the invention were designed to enrich the sample in heteroduplex in order to enable the detection of mutations which would normally go undetected. The steps of the method of the invention can be reiterated a plurality of times to increase the purity and quantity of heteroduplex to any desired level. The increased amount of heteroduplex compared to homoduplex obtained in this manner can be described by an "enhancement factor". The "enhancement factor" is defined herein as the increase in the ratio of heteroduplex to homoduplex compared to the ratio of heteroduplex to homoduplex in the original hybridized sample, wherein the increase results from the implementation of the method of the invention. The "enhancement factor" depends on the number of iterations performed and can range from 10 to more than 1,000.

After the final iteration, the PCR product is hybridized and analyzed by DMIPC. If the original sample contained a mutation, the concentration of heteroduplex or its concentration relative to wild type, will now be sufficient to detect. The DMIPC chromatogram will, therefore, show a peak having the retention time of the standard heteroduplex. In this event it can be concluded unambiguously that a mutation was present in the original sample.

As a further confirmation of the identity of the mutation, an aliquot of standard heteroduplex can be mixed with an aliquot of the heteroduplex enriched sample. A DMIPC chromatogram of this mixture will show an increase in the area of the heteroduplex peak, compared to the area of the heteroduplex enriched sample peak alone.

Additionally, the purification and enrichment method described above will provide sufficient heteroduplex for determination of its base pair sequence.

Sequencing will provide further confirmation of the identity of the mutation.

If, after performing a plurality of iterations according to the method of the invention as described above no heteroduplex peak is seen in the DMIPC chromatogram, then it can be safely concluded that the original sample did not contain a mutation.

Denaturing gradient gel electrophoresis techniques which can separate homoduplexes from heteroduplexes cannot be used as an alternative to DMIPC. Although samples can be recovered from gels with difficulty, blind collection is not possible because the mobility of a DNA fragment in a gel is not constant. Therefore, its position cannot be reliably predicted. In addition, the shape of DNA fragment bands in gels are often irregular, further complicating sample recovery and making detection uncertain. An additional problem is the fact that gels take many hours to develop, making this method impractical for routine use.



On the other hand, the highly predictable nature of the retention times determined from DMIPC separations make this method uniquely suited to mutation detection if blind collection is required. The use of DMIPC for the purpose of mutation detection as described in this application has not been previously reported.

The detection of cancer cells in early diagnosis screens or in evaluations of a cancer treatment regimen is usually about 1 cancer cell in 100 total cells, or 1%. Thus, cancer cells which are present below the 1% level will not be seen by traditional analytical methods. By providing an enhancement factor of 1000, the present invention increases the sensitivity of cancer cell detection to about 1

15. A method of claim 14 including amplifying the fractions collected in step (d) using PCR to obtain an increased amount of heteroduplex relative to homoduplex.
16. A method of claim 14 including repeating steps (a) through (d).
- 5 17. A method of claim 14 wherein said DNA sample contains a large background of wild type.
18. A method of claim 14 wherein said mutant DNA is below the limit of detection.
19. A method of claim 14 including confirming the identity of the heteroduplex
10 obtained.
20. A method of claim 14 wherein the DNA sequence of the wild type DNA and the mutant DNA are known.
21. A method of claim 14 wherein the mutant DNA differs from wild type DNA by at least one base pair.
- 15 22. A method of claim 14, wherein the same primers are used to amplify both the mutant DNA and the wild type DNA in the sample.
23. A method of claim 14 wherein the retention time used in the blind collection of the heteroduplex in step (d) was previously determined from a reference standard.
- 20 24. A method of claim 1 wherein the separation of the product by Denaturing Matched Ion Polynucleotide Chromatography is effected with an MIPC column containing a stationary phase separation media, and the column is treated before the separating step with a solution for removing any residual DNA from prior separations.

25. A method of claim 24 wherein the column is treated before the separating step with from 50 μ L to 1 ml of tetrasodium EDTA adjusted to a pH of 13 with sodium hydroxide.

1/2

*FIG.-1**FIG.-2*

2/2




FIG.-3

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/23265

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : 495/6, 91.1, 91.2; 536/23.1, 24.3, 24.33, 25.4; 210/635

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 495/6, 91.1, 91.2; 536/23.1, 24.3, 24.33, 25.4; 210/635

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,585,236 A (BONN et al) 17 December 1996 (12/17/96), see entire document column 9, lines 44-60.	1-25
Y,P	US 5,795,976 A (OEFNER et al) 18 August 1998 (08/18/98), see entire document especially abstract.	1-25
Y	US 4,683,202 A (MULLIS) 28 July 1987 (07/28/87), see entire document.	1-25
Y	HUBER, C.G. et al. High-Resolution Liquid Chromatography of Oligonucleotides on Nonporous Alkylated Styrene-Divinylbenzene Copolymers. Analytical Biochemistry. 1993, Vol. 212, pages 351-358, see entire document.	1-25

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 JANUARY 1999

Date of mailing of the international search report

05 FEB 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

GARY JONES

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/23265

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C12Q 1/68; C12P 19/34; C07H 21/02, 21/04, 21/00; B01D 15/08; C02F 1/28

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN ,WPIDS,BIOSIS, MEDLINE,CANCERLIT, BIOTECHDS, LIFESCI,CAPLUS,EMBASE

search terms: MIPC, matched ion polynucleotide chromatography, chromatography, pcr, amplif, heteroduplex, mutation, hplc